BYSI Stock Overview
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BeyondSpring Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.29 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$0.65 |
| Beta | 0.17 |
| 1 Month Change | -26.60% |
| 3 Month Change | 154.44% |
| 1 Year Change | 129.00% |
| 3 Year Change | -78.84% |
| 5 Year Change | -84.73% |
| Change since IPO | -86.37% |
Recent News & Updates
Recent updates
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
Jun 21
BeyondSpring, Beyond Salvage
Feb 03Circling Back On BeyondSpring
Nov 16Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns
Sep 18BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk
Sep 07BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space
Aug 01BeyondSpring EPS misses by $0.04
Jun 16BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia
Jun 07FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%
Jun 01BeyondSpring EPS misses by $0.17
Apr 30How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?
Dec 22
BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution
Dec 15BeyondSpring slides 9% on public offering pricing at $10.0/share
Nov 19BeyondSpring under pressure on shares offering
Nov 17BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial
Nov 16Shareholder Returns
| BYSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 27.2% | -2.5% | -3.2% |
| 1Y | 129.0% | -3.7% | 19.3% |
Return vs Industry: BYSI exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: BYSI exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| BYSI volatility | |
|---|---|
| BYSI Average Weekly Movement | 27.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BYSI's share price has been volatile over the past 3 months.
Volatility Over Time: BYSI's weekly volatility has increased from 17% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 73 | Lan Huang | beyondspringpharma.com |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company’s lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.
BeyondSpring Inc. Fundamentals Summary
| BYSI fundamental statistics | |
|---|---|
| Market cap | US$82.32m |
| Earnings (TTM) | -US$27.51m |
| Revenue (TTM) | US$1.55m |
57.6x
P/S Ratio-3.2x
P/E RatioIs BYSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BYSI income statement (TTM) | |
|---|---|
| Revenue | US$1.55m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.55m |
| Other Expenses | US$29.06m |
| Earnings | -US$27.51m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,774.84% |
| Debt/Equity Ratio | 0% |
How did BYSI perform over the long term?
See historical performance and comparison